Abstract: A human oral care composition, includes safe and effective amounts of the fluoride ion and stabilized chlorine dioxide, that may take the form of a paste, gel, rinse, spray, powder, varnish or similar that reduces demineralization and promotes remineralization of teeth. The method includes the topical application of the composition to the human oral cavity (including but not limited to the teeth, gingiva, and tongue), preferably at least once daily, to enhance the anti-caries effect of fluoride by released chlorine dioxide compromising any biofilm present.

Abstract: Various embodiments described herein provide for a multi-component compositions and methods for its pharmaceutical and cosmetic use, comprising a combination of an aliphatic anionic compound, an oxidative compound, and a buffering system. Source of fluoride ion and other carriers are optional ingredients. The aliphatic anionic compound and the oxidative compound function together, in presence or absence of fluoride ion source, to protect the oxidative compounds from degradation prior to use and upon use, and to enhance the efficacy of the composition. In addition to achieving greater stability, combined effects of the aliphatic anionic compound, oxidative compound and source of fluoride ion achieve enhanced fluoride uptake, higher enamel protection by enhanced remineralization and reduced demineralization, increased plaque removal, reduced re-growth of plaque polymicrobial biofilm, greater amount of chlorite ion availability and effective oxidation of salivary biomolecules.

Abstract: Described herein are single-phase compositions and methods for its pharmaceutical and cosmetic use, comprising (i) a combination of N-acyl sarcosinate, (ii) an oxidative compound, and (iii) a buffering system in amounts and embodiments effective to protect the oxidative compounds from degradation prior to use and upon use and to enhance the efficacy of the composition in removing polymicrobial biofilms, reducing the re-growth of polymicrobial biofilms that leads to plaque formation, greater availability of chlorite ion for antimicrobial and cosmetic purposes, and effective oxidation of salivary biomolecules. When these single-phase compositions are comprised of a source of fluoride ion, they also achieve enhanced enamel fluoride uptake, higher enamel protection by enhanced remineralization and reduced demineralization of teeth when compared to US Pharmacopoeia Reference Dentifrice, prior known toothpastes comprising stabilized chlorine dioxide and comparable commercial dentifrices.

Abstract: Some embodiments described herein provide for a multi-component compositions and methods for its pharmaceutical and cosmetic use, comprising a combination of an aliphatic anionic compound, an oxidative compound, and a buffering system. Source of fluoride ion and other carriers are optional ingredients. The aliphatic anionic compound and the oxidative compound function together, in presence or absence of fluoride ion source, to protect the oxidative compounds from degradation prior to use and upon use, and to enhance the efficacy of the composition. In addition to achieving greater stability, combined effects of the aliphatic anionic compound, oxidative compound and source of fluoride ion achieve enhanced fluoride uptake, higher enamel protection by enhanced remineralization and reduced demineralization, increased plaque removal, reduced re-growth of plaque polymicrobial biofilm, greater amount of chlorite ion availability and effective oxidation of salivary biomolecules.

Abstract: Described herein are single-phase multi-component compositions and methods for their use reducing the viral load of infectious viruses on host organisms, including but not limited to Influenza A, Rhinovirus Type 14, Adenovirus Type 5, Herpes Simplex Virus Type 1, Herpes Simplex Virus Type 2, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2; COVID-19 virus), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), and Human coronavirus 229E. The compositions described herein comprise a combination of an oxidative compound and a buffering system. The methods of use of these compositions as antiviral agents when applied to the oral, nasal, ocular, aural, anal, and urogenital cavities are described. Data shows the compositions to be effective in reducing influenza A and the human coronaviruses. In that regard, the single-phase multi-component compositions and methods for its antiviral use disclosed herein may be offer a single, effective product to combat multiple, concurrent pandemics.

Abstract: The composition and method for the use of stabilized chlorine dioxide as an antimicrobial agent against oral microorganisms for the treatment and prevention of halitosis and prevention of oral diseases, wherein the activation and release of chlorine dioxide from the composition a) occurs rapidly and without a period of induction, b) results from the oxidative reduction and consumption of amino acids and volatile sulfur compound precursors, and c) generates twice the available chlorine dioxide gas as that generated from simply lowering the pH of the composition. The preferred concentrations of stabilized chlorine dioxide in this invention are in the range of 0.005% to 2.0% (w/v) wherein the pH of the composition is initially lowered by a citrate and then stabilized by a peroxy compound.

Abstract: Described herein are single-phase compositions and methods for its pharmaceutical and cosmetic use, comprising (i) a combination of N-acyl sarcosinate, (ii) an oxidative compound, and (iii) a buffering system in amounts and embodiments effective to protect the oxidative compounds from degradation prior to use and upon use and to enhance the efficacy of the composition in removing polymicrobial biofilms, reducing the re-growth of polymicrobial biofilms that leads to plaque formation, greater availability of chlorite ion for antimicrobial and cosmetic purposes, and effective oxidation of salivary biomolecules. When these single-phase compositions are comprised of a source of fluoride ion, they also achieve enhanced enamel fluoride uptake, higher enamel protection by enhanced remineralization and reduced demineralization of teeth when compared to US Pharmacopoeia Reference Dentifrice, prior known toothpastes comprising stabilized chlorine dioxide and comparable commercial dentifrices.

Abstract: A composition and method of stabilized chlorine dioxide at a concentration range of about 0.005% to about 0.800% (w/v) at a pH in the range of 6.0 to 7.4 for the prevention of oral diseases caused by dental biofilm and plaque accumulation, such as gingivitis and periodontitis, through bactericidal properties is disclosed. The bactericidal properties of stabilized chlorine dioxide are further expanded to include reduction (kill) of anaerobic/aerobic/facultative gram-negative and gram-positive oral bacteria occurring in plaque or polymicrobial biofilms. The composition may be in the form of wash, rinse, soak, paste, gel, aerosol spray, or other suitable delivery system.

Abstract: A method and composition for preventing and treating all forms of osteonecrosis of the jaw are disclosed. The composition is comprised of 0.005%-2.0% weight/volume (w/v) chlorine dioxide source, such as sodium chlorite, chlorite ion, stabilized chlorine dioxide or similar and may take the form of a paste, gel, rinse, spray, powder, varnish or similar. The method for treatment and prevention includes the application of the composition in the oral cavity and other body areas affected by osteonecrosis of the jaw.

Abstract: A method for determining the available treatment dosage of stabilized chlorine dioxide in the prevention and the treatment of plaque accumulation, volatile sulfur compound production, gingivitis and periodontitis, and for differentiating the treatment dosage from other chlorine-containing compounds that may not have such beneficial effects is disclosed. When in solution as stabilized chlorine dioxide, the presence of other ions such as chlorate and chloride may not only obscure results as to the concentration of stabilized ClO2, but also reduce the predicted effectiveness. The present invention uses validated analytical methods to predict the effectiveness of stabilized ClO2 by more precisely measuring its concentration in solution. Such measurement renders precision at a level required of food-grade and pharmacy-grade chemotherapeutic agents in the oral cavity. Preferred concentrations are within the range of about 0.005 to about 2% (w/v) stabilized chlorine dioxide.

Abstract: A method and composition for preventing and treating all forms of osteonecrosis of the jaw are disclosed. The composition is comprised of 0.005%-2.0% weight/volume (w/v) chlorine dioxide source, such as sodium chlorite, chlorite ion, stabilized chlorine dioxide or similar and may take the form of a paste, gel, rinse, spray, powder, varnish or similar. The method for treatment and prevention includes the application of the composition in the oral cavity and other body areas affected by osteonecrosis of the jaw.

Abstract: A composition of stabilized chlorine dioxide at a concentration range of about 0.0004% to about 0.8% (w/v) having anti fungal properties to prevent oral fungal infections and method of use are disclosed.

Abstract: A stable solution cream, salve, or spray composition containing activated stabilized chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonoas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.

Abstract: A stable solution, cream, salve, or spray composition containing activated chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the treatment of vaginitis and endometriosis by reducing any of Candida, Actinobacillus actinomycetemcomitans, Pseudomonades, and Porphyromonas gingivalis present in the vagina or the uterus. The preferred concentration ranges are in the range of about 0.005% to about 2.0% of chlorine dioxide, and in the range of about 0.02% to about 3.0% of phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.4, at which pH chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.

Abstract: A stable solution, cream, salve, or spray composition containing chlorine dioxide and a phosphate, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices brought about by any of leukoplakia, hairy leukoplakia, vaginitis, endometriosis, Candida Albicans, Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Pseudomonades, Candida species, and leukoplakia vulvae. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.

Abstract: A method for oxidatively consuming volatile sulfur compounds selected from the group consisting of dimethylsulfide, hydrogen sulfide, and methylmercaptan at the epithelial barrier of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices to maintain the epithelial barrier and reduce penetration of any of Candida, Actinobacillus actinomycetumcomitans, Pseudomonades, and Porphyromonas gingivalis, said method comprising the step of applying to the orifices a composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains chlorine dioxide in a concentration in the range of about 0.005% to about 2.0% and a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodiuit phosphate, or sodium monofluorophosphate in a concentration in the range of about 0.02% to about 3.

Abstract: A stable solution, cream, salve, or spray composition containing chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are in the range of about 0.005% to about 2.0% chlorine dioxide, and in the range of about 0.02% to about 3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of about 6.0 to about 7.

Abstract: A stable mouth wash or dentifrice composition containing stabilized chlorine dioxide and phosphates is disclosed for reducing the motility of and killing microbial pathogens. The preferred concentration ranges are between about 0,005%-0.5% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate retards escape of chlorine dioxide in the pH range (6.0 to 7.4) typically found in a mouth.

Abstract: A stable mouth wash or dentifrice composition containing stabilized chlorine dioxide and phosphates is disclosed for reducing the motility of and killing microbial pathogens. The preferred concentration ranges are between about 0.005%-0.5% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate retards escape of chlorine dioxide in the pH range (6.0 to 7.4) typically found in a mouth.